A novel oral formulation (CoM pat. pend.) of HP‐alpha‐cyclodextrin as a safe (not ototoxic) and convenient (oral) drug against Alzheimer’s disease

There are few, if any, disease‐modifying treatments (DMTs) for AD. HP‐beta‐cyclodextrin (HPβCD) was effective in AD models and ph1/2 trials of overnight IV HPβCD qow showed reduction of CSF tau protein, but also confirmed its risk of cholesterol‐related ototoxicity. As the hearing loss seen in these short (12 wk) trials was only transient (Fig. 1), the FDA accepted INDs for IV HPβCD as a drug against NPC1 (ph3) and AD (ph2).